Baxter International Inc

Latest Results (12.11.2025):

Baxter International Inc.'s second-quarter 2025 results demonstrate steady performance with global continuing operations sales of approximately $2.81 billion, modest growth across key segments, and earnings in line with guidance. The results highlight GAAP diluted EPS of $0.24 and adjusted diluted EPS of $0.59, along with strong segment performance and strategic advancements, including the appointment of Andrew Hider as the new CEO.

Sales Performance

Worldwide continuing operations sales reached about $2.81 billion, marking a 4% increase on a reported basis and a 1% operational rise. U.S. sales were approximately $1.54 billion (up 3% reported, down 1% operationally), and international sales achieved roughly $1.27 billion, increasing 6% reported and 3% operationally.

Earnings Results

The company delivered U.S. GAAP net income of $122 million, equating to $0.24 per diluted share. On an adjusted basis, diluted EPS was $0.59, representing a 28% increase over the prior year, aligning with the company’s previously issued guidance.

Segment Performance

In the Medical Products & Therapies segment, sales were around $1.32 billion, flat on a reported basis with a 1% operational increase. Healthcare Systems & Technologies generated approximately $767 million (up 3% reported and 2% operationally), while Pharmaceuticals reached about $612 million, with modest growth of 2% reported and 1% operationally.

Strategic Highlights

Baxter emphasized its focus on innovation and sustainable growth, as exemplified by the recent appointment of Andrew Hider as president and CEO. Additionally, the company highlighted progress in strategic initiatives including inventory restoration post-Hurricane Helene and the expansion of its Vizient Reserve Program to ensure reliable access to critical IV solutions.

Financial Outlook

Looking ahead to full-year 2025, Baxter expects continuing operations' sales growth of 6-7% on a reported basis and 3-4% operationally, with adjusted earnings between $2.42 to $2.52 per diluted share. For the third quarter, the outlook includes sales growth of 6-7% reported and 3-4% operationally, with expected adjusted EPS of $0.58 to $0.62.